Riemann-Liouville Fractional Cosine Functions

In this paper, a new notion, named Riemann-Liouville fractional cosine function is presented. It is proved that a Riemann-Liouville $\alpha$-order fractional cosine function is equivalent to Riemann-Liouville $\alpha$-order fractional resolvents introduced in [Z.D. Mei, J.G. Peng, Y. Zhang, Math. Nachr. 288, No. 7, 784-797 (2015)]

3,9-Dichloro-2,4,8,10-tetra­oxa-3,9-di­phosphaspiro­[5.5]undecane-3,9-dione

In the title compound, C5H8Cl2O6P2, the two six-membered rings display chair conformations. The P=O bond distances are 1.444 (2) and 1.446 (2) Å. Weak inter­molecular C—H⋯O hydrogen bonds are present in the crystal structure

YKL-40 promotes chemokine expression following drug-induced liver injury via TF-PAR1 pathway in mice

Background: The inflammatory factor YKL-40 is associated with various inflammatory diseases and is key to remodeling inflammatory cells and tissues. YKL-40 (Chi3l1) promotes the activation of tissue factor (TF), leading to intrahepatic vascular coagulation (IAOC) and liver injury. TF is a key promoter of the exogenous coagulation cascade and is also involved in several signaling involving cell proliferation, apoptosis, charring, migration and inflammatory diseases pathways. However, the effect of YKL-40-induced TF-PAR1 pathway on the expression of downstream chemokines remains unknown.Methods: We established a liver injury model using Concanavalin A (ConA) in C57 BL/6 mice. By adopting various experimental techniques, the effect of YKL-40 induced TF-PAR1 pathway on the expression of downstream chemokine ligand 2 (CCL2) and IP-10 was verified.Results: We found that overexpression of YKL-40 increased the expression of TF, protease-activated receptor 1 (PAR1), CCL2 and IP-10 in mice and exacerbated the severity of liver injury. However, blocking the expression of TF significantly reversed the extent of liver injury.Conclusion: We found that YKL-40 promotes the expression of downstream chemokines ligand 2 (CCL2) and IP-10 by activating the TF-PAR1 pathway, leading to increased recruitment of inflammatory cells and exacerbating the progression of liver injury. This provides a new approach for the clinical treatment of drug-induced liver injury